08/19/2016 primabolan-la-pharma-30-tabs-25mg-tab

primobolan for women

Primobolan for women has immunomodulatory, hemostimulating, detoxifying, hepatoprotective action, inhibits tumor cell drug resistance to antibiotics anthracyclines, alkylating agents; It allows to overcome drug resistance Mycobacterium tuberculosis isoniazid associated with genes katG (catalase-peroxidase gene) and inhA (gene enol-ACP reductase). Primobolan for women ® potentiates the effect of doxorubicin to the tumor cells, chemotherapy agents (isoniazid, rifampicin, rifabutin, cycloserine, capreomycin, levofloxacin, a cationic antimicrobial peptide kataletsidina) on Mycobacterium tuberculosis.
Immunomodulatory effects Primobolan for women drug ® is due to receptor-mediated effects on calcium-dependent signaling pathways of macrophages, which leads to an increase in:
– viability and functional capacity of the tissue macrophages;
– exocytosis submembrane pellets intracellularly parasitic forms of Mycobacterium tuberculosis;
– the activity of lysosomal enzymes;
– generation of reactive oxygen species;
– absorption and microbial death;
– cytokine: interleukin 1, interleukin 6 , tumor necrosis factor, interferons, erythropoietin, interleukin 2; . protivomikrobngh cationic peptides – defensins, kataletsidinov
hemostimulating action Primobolan for women ® is due to receptor-mediated enhancement of bone marrow hematopoiesis: erythropoiesis processes lymphopoiesis and granulocyte-monocytopoiesis. Action on the progenitor cells of different lines of blood cells is mediated by the functioning of the MAP- and inositol kinase systems, increases the stability of the differentiated hematopoietic cells, restores their sensitivity to the action of endogenous factors hematopoiesis.
Detoxifying and hepatoprotective effects of the drug are due to receptor-mediated enhancement of expression of enzymes of the second phase detoxification of xenobiotics, including glutathione, glutathione peroxidase, glutathione-S-transferase, glucose-6-phosphate dehydrogenase, heme oxygenase-1, increase the intracellular level of glutathione, providing protection of cellular structures against toxic radicals action.
Primobolan for women ® has a direct ingi-biruyuschee effect on the activity of factor multidrug resistance of tumor cells – the protein is P-glycoprotein (Pgp), which determines the resistance of tumor cells to chemotherapy agents, including anthracycline antibiotics, drugs alkylating action.
Primobolan for women ® initiates a reaction of transformation of isoniazid – prodrug thereof, in a pharmacologically active form – isonicotinic acid having bacteriostatic effect on Mycobacterium tuberculosis, that can overcome drug resistance of Mycobacterium tuberculosis, caused by negative transforming gene katG (catalase-peroxidase gene) and inhA (enol-ACP reductase gene).
Primobolan for women ® stimulates exocytosis of vesicle of the macrophage intracellular parasitic pathogens including . Mycobacterium tuberculosis, ensuring their removal from the pharmacological shelters and making available to the action of antibacterial drugs, including isoniazid, rifampicin, rifabutin, cycloserine, capreomycin, levofloxacin
Primobolan for women ® enhances the secretion of cationic peptides – defensins and kataletsidinov macrophages, stimulates uptake of Mycobacterium tuberculosis, defining indirect antibacterial drug.

Pharmacokinetics
Primobolan for women ® belongs to a group of natural metabolites that determines the characteristics of its metabolism by existing cellular enzymatic systems. After intramuscular, intravenous or subcutaneous injection is greater than 90% bioavailability. It noted a linear relationship between dose and concentration of drug in blood plasma. Maksialnaya plasma concentrations observed after intravenous injection over 2-5 minutes, intramuscular -. For 7-10 min. As a natural peptide product, Primobolan for women ® is metabolized in organs and tissues of the body with elimination through the kidneys.

Indications

Primobolan for women ® is used in adults as a means of prevention and treatment of secondary immunodeficient states associated with radiation, chemical and infectious factors for restoring suppressed immune reactions and the oppressed state of bone marrow hematopoiesis; to increase resistance to a variety of pathological influences – infectious agents, chemical and / or physical factors (intoxication, radiation, etc.); as a hepatoprotective agent in chronic viral hepatitis B and C; to potentiate the therapeutic effects of antibacterial therapy of chronic obstructive lung disease; for the prevention of postoperative septic complications. Injection of 10 and 30 mg / ml is used as part of a comprehensive anti-tuberculosis treatment of severe forms of TB spread in all locations, in the presence of drug resistance of Mycobacterium tuberculosis, for the prevention of exacerbations of chronic hepatitis B in patients with tuberculosis on the background of anti-TB therapy, for the treatment of toxic complications of TB therapy. The solution for injection is used in the complex therapy of psoriasis, including moderate and severe forms of the presence of erythroderma, arthropathy.
Primobolan for women used in the treatment of malignant neoplasms. Primobolan for women ® is used in oncology for the prevention and treatment of toxic effects of chemo and radiation therapy (hemodialysis and helping to reduce hepatotoxicity). Primobolan for women ® promotes efficient recovery functions of bone marrow hematopoiesis during anticancer therapy. Primobolan for women ® removes or smoothes the non-specific manifestations of the disease syndrome (anemia, fatigue, decreased appetite, increased pain sensitivity).

Contraindications

Use of the drug is contraindicated in cases of individual intolerance, pregnancy, lactation.

Dosing and Administration

Primobolan for women ® is administered intravenously, intramuscularly, subcutaneously. Assign daily 5-40 mg (1 course – 50-300 mg). Depending on the nature of the disease
From prevention to drug is used daily by intramuscular injection 5-10 mg for 2 weeks.
In the complex therapy of tuberculosis Primobolan for women ® 60 mg is administered 1 time per day the first 10 days daily intramuscular injection, the next 20 days Primobolan for women ® 60 mg intramuscularly every other day, one injection per day.
If necessary, a second course of treatment after 1-6 months.
in the complex treatment of psoriasis Primobolan for women ® is used daily by intramuscular injection a daily dose of 10 mg for 15 days, then for additional 2 weeks, 5 times a week in a daily dose of 10 mg. Total 25 injections per course of treatment.
As a means of maintenance chemotherapy in oncology Primobolan for women 60 mg administered subcutaneously for 1.5-2 hours before the application of anti-tumor agents. Further, between courses of chemotherapy Primobolan for women ® 60 mg administered subcutaneously every other day. The next course of chemotherapy regimen of the drug is repeated.
As a means of tracking radiation therapy Primobolan for women ® 60 mg administered subcutaneously every 0.5-1 hour after the next session of irradiation every other day throughout the course of radiation therapy.
Primobolan for women ® can be administered in the same syringe with water-soluble drugs.

Side effect

In some patients there may be a slight rise in temperature (up to 37,1 ° C – 37,5 ° C), pain at the injection site of the drug. In poor subjective tolerance of pain Primobolan for women ® is administered together with 1-2 ml of 0.5% solution of novocaine. steroiden kaufen

steroide kaufen deutschland

anabolika steroide kaufen